{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,5]],"date-time":"2026-09-05T01:33:04Z","timestamp":1788571984472,"version":"build-2803163510"},"reference-count":110,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2018,8,13]],"date-time":"2018-08-13T00:00:00Z","timestamp":1534118400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"funder":[{"name":"Clinical Research Fund of the University Hospitals Leuven"},{"name":"Fund for Scientific Research","award":["G0B1313N"],"award-info":[{"award-number":["G0B1313N"]}]},{"name":"European Society for Pediatric Nephrology"},{"DOI":"10.13039\/501100002661","name":"Fonds De La Recherche Scientifique - FNRS","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100002661","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Pediatr Nephrol"],"published-print":{"date-parts":[[2019,6]]},"DOI":"10.1007\/s00467-018-4004-5","type":"journal-article","created":{"date-parts":[[2018,8,13]],"date-time":"2018-08-13T06:18:37Z","timestamp":1534141117000},"page":"993-1008","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":35,"title":["Oxidative stress in autosomal dominant polycystic kidney disease: player and\/or early predictor for disease progression?"],"prefix":"10.1007","volume":"34","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0280-311X","authenticated-orcid":false,"given":"Asmin","family":"Andries","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kristien","family":"Daenen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fran\u00e7ois","family":"Jouret","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bert","family":"Bammens","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Djalila","family":"Mekahli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ann","family":"Van Schepdael","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2018,8,13]]},"reference":[{"key":"4004_CR1","doi-asserted-by":"publisher","first-page":"65","DOI":"10.2147\/CEOR.S76269","volume":"7","author":"SM Brunelli","year":"2015","unstructured":"Brunelli SM, Blanchette CM, Claxton AJ, Roy D, Rossetti S, Gutierrez B (2015) End-stage renal disease in autosomal dominant polycystic kidney disease: a comparison of dialysis-related utilization and costs with other chronic kidney diseases. Clin Outcomes Res 7:65\u201372","journal-title":"Clin Outcomes Res"},{"key":"4004_CR2","first-page":"1","volume":"29","author":"E Cornec-Le Gall","year":"2017","unstructured":"Cornec-Le Gall E, Torres VE, Harris PC (2017) Genetic complexity of autosomal dominant polycystic kidney and liver diseases. J Am Soc Nephrol 29:1\u201311","journal-title":"J Am Soc Nephrol"},{"key":"4004_CR3","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1038\/ng0697-179","volume":"16","author":"F Qian","year":"1997","unstructured":"Qian F, Germino FJ, Cai Y, Zhang X, Somlo S, Germino GG (1997) PKD1 interacts with PKD2 through a probable coiled-coil domain. Nat Genet 16:179\u2013183","journal-title":"Nat Genet"},{"key":"4004_CR4","doi-asserted-by":"publisher","first-page":"6965","DOI":"10.1073\/pnas.94.13.6965","volume":"94","author":"L Tsiokas","year":"1997","unstructured":"Tsiokas L, Kim E, Arnould T, Sukhatme VP, Walz G (1997) Homo- and heterodimeric interactions between the gene products of PKD1 and PKD2. Proc Natl Acad Sci U S A 94:6965\u20136970","journal-title":"Proc Natl Acad Sci U S A"},{"key":"4004_CR5","doi-asserted-by":"publisher","first-page":"1193","DOI":"10.1016\/j.ajhg.2016.05.004","volume":"98","author":"B Porath","year":"2016","unstructured":"Porath B, Gainullin VG, Cornec-Le Gall E, Dillinger EK, Heyer CM, Hopp K, Edwards ME, Madsen CD, Mauritz SR, Banks CJ, Baheti S, Reddy B, Herrero JI, Ba\u00f1ales JM, Hogan MC, Tasic V, Watnick TJ, Chapman AB, Vigneau C, Lavainne F, Audr\u00e9zet MP, Ferec C, Le Meur Y, Torres VE, Harris PC (2016) Mutations in GANAB, encoding the glucosidase II\u03b1 subunit, cause autosomal-dominant polycystic kidney and liver disease. Am J Hum Genet 98:1193\u20131207","journal-title":"Am J Hum Genet"},{"key":"4004_CR6","doi-asserted-by":"publisher","first-page":"32","DOI":"10.2174\/1573402111309010006","volume":"9","author":"GM Fick-Brosnahan","year":"2013","unstructured":"Fick-Brosnahan GM (2013) Endothelial dysfunction and angiogenesis in autosomal dominant polycystic kidney disease. Curr Hypertens Rev 9:32\u201336","journal-title":"Curr Hypertens Rev"},{"key":"4004_CR7","doi-asserted-by":"publisher","first-page":"184","DOI":"10.1053\/j.ajkd.2007.09.020","volume":"51","author":"D Wang","year":"2008","unstructured":"Wang D, Strandgaard S, Borresen ML, Luo Z, Connors SG, Yan Q, Wilcox CS (2008) Asymmetric dimethylarginine and lipid peroxidation products in early autosomal dominant polycystic kidney disease. Am J Kidney Dis 51:184\u2013191","journal-title":"Am J Kidney Dis"},{"key":"4004_CR8","doi-asserted-by":"publisher","first-page":"622","DOI":"10.1007\/s10157-012-0611-9","volume":"16","author":"E Higashihara","year":"2012","unstructured":"Higashihara E, Horie S, Muto S, Mochizuki T, Nishio S, Nutahara K (2012) Renal disease progression in autosomal dominant polycystic kidney disease. Clin Exp Nephrol 16:622\u2013628","journal-title":"Clin Exp Nephrol"},{"key":"4004_CR9","first-page":"69","volume":"3","author":"CR Halvorson","year":"2010","unstructured":"Halvorson CR, Bremmer MS, Jacobs SC (2010) Polycystic kidney disease: inheritance, pathophysiology, prognosis, and treatment. Int J Nephrol Renovasc Dis 3:69\u201383","journal-title":"Int J Nephrol Renovasc Dis"},{"key":"4004_CR10","doi-asserted-by":"publisher","first-page":"190","DOI":"10.1038\/ki.1984.154","volume":"26","author":"DN Churchill","year":"1984","unstructured":"Churchill DN, Bear JC, Morgan J, Payne RH, McManamon PJ, Gault MH (1984) Prognosis of adult onset polycystic kidney disease re-evaluated. Kidney Int 26:190\u2013193","journal-title":"Kidney Int"},{"key":"4004_CR11","doi-asserted-by":"publisher","first-page":"750","DOI":"10.1038\/nrneph.2017.127","volume":"13","author":"MB Lanktree","year":"2017","unstructured":"Lanktree MB, Chapman AB (2017) New treatment paradigms for ADPKD: moving towards precision medicine. Nat Rev Nephrol 13:750\u2013768","journal-title":"Nat Rev Nephrol"},{"key":"4004_CR12","doi-asserted-by":"publisher","first-page":"342","DOI":"10.1093\/ndt\/gfw013","volume":"32","author":"KL Nowak","year":"2017","unstructured":"Nowak KL, Farmer H, Cadnapaphornchai MA, Gitomer B, Chonchol M (2017) Vascular dysfunction in children and young adults with autosomal dominant polycystic kidney disease. Nephrol Dial Transplant 32:342\u2013347","journal-title":"Nephrol Dial Transplant"},{"key":"4004_CR13","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1038\/nrneph.2009.13","volume":"5","author":"T Ecder","year":"2009","unstructured":"Ecder T, Schrier R (2009) Cardiovascular abnormalities in autosomal-dominant polycystic kidney disease. Nat Rev Nephrol 5:221\u2013228","journal-title":"Nat Rev Nephrol"},{"key":"4004_CR14","doi-asserted-by":"publisher","first-page":"1381","DOI":"10.1046\/j.1523-1755.2003.00236.x","volume":"64","author":"D Wang","year":"2003","unstructured":"Wang D, Iversen J, Wilcox CS, Strandgaard S (2003) Endothelial dysfunction and reduced nitric oxide in resistance arteries in autosomal-dominant polycystic kidney disease. Kidney Int 64:1381\u20131388","journal-title":"Kidney Int"},{"key":"4004_CR15","doi-asserted-by":"crossref","first-page":"1371","DOI":"10.1681\/ASN.V1181371","volume":"11","author":"D Wang","year":"2000","unstructured":"Wang D, Iversen J, Strandgaard S (2000) Endothelium-dependent relaxation of small resistance vessels is impaired in patients with autosomal dominant polycystic kidney disease. J Am Soc Nephrol 11:1371\u20131376","journal-title":"J Am Soc Nephrol"},{"key":"4004_CR16","doi-asserted-by":"publisher","first-page":"1198","DOI":"10.1152\/ajprenal.00327.2014","volume":"307","author":"J Klawitter","year":"2014","unstructured":"Klawitter J, Reed-Gitomer BY, McFann K, Pennington A, Klawitter J, Abebe KZ, Klepacki J, Cadnapaphornchai MA, Brosnahan G, Chonchol M, Christians U, Schrier RW (2014) Endothelial dysfunction and oxidative stress in polycystic kidney disease. Am J Physiol Renal Physiol 307:1198\u20131206","journal-title":"Am J Physiol Renal Physiol"},{"key":"4004_CR17","doi-asserted-by":"publisher","first-page":"1272","DOI":"10.1093\/ndt\/gfg074","volume":"18","author":"F Locatelli","year":"2003","unstructured":"Locatelli F, Canaud B, Eckardt K-U, Stenvinkel P, Wanner C, Zoccali C (2003) Oxidative stress in end-stage renal disease: an emerging threat to patient outcome. Nephrol Dial Transplant 18:1272\u20131280","journal-title":"Nephrol Dial Transplant"},{"key":"4004_CR18","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1097\/WOX.0b013e3182439613","volume":"5","author":"E Birben","year":"2012","unstructured":"Birben E, Murat U, Md S, Sackesen C, Erzurum S, Kalayci O (2012) Oxidative stress and antioxidant defense. World Allergy Organ J 5:9\u201319","journal-title":"World Allergy Organ J"},{"key":"4004_CR19","doi-asserted-by":"publisher","first-page":"393","DOI":"10.13075\/mp.5893.00137","volume":"66","author":"M Czerska","year":"2015","unstructured":"Czerska M, Miko\u0142ajewska K, Zieli\u0144ski M, Gromadzi\u0144ska J, W\u0105sowicz W (2015) Today\u2019s oxidative stress markers. Med Pr 66:393\u2013405","journal-title":"Med Pr"},{"key":"4004_CR20","doi-asserted-by":"crossref","unstructured":"Drozdz D, Kwinta P, Sztefko K, Kordon Z, Drozdz T, \u0141\u0105tka M, Miklaszewska M, Zachwieja K, Rudzi\u0144ski A, Pietrzyk JA (2016) Oxidative stress biomarkers and left ventricular hypertrophy in children with chronic kidney disease. Oxidative Med Cell Longev 2016:7520231","DOI":"10.1155\/2016\/7520231"},{"key":"4004_CR21","doi-asserted-by":"publisher","first-page":"451","DOI":"10.1038\/nrneph.2015.39","volume":"11","author":"FT Chebib","year":"2015","unstructured":"Chebib FT, Sussman CR, Wang X, Harris PC, Torres VE (2015) Vasopressin and interactive calcium, cyclic AMP and purinergic signaling in polycystic kidney disease. Nat Rev Nephrol 11:451\u2013464","journal-title":"Nat Rev Nephrol"},{"key":"4004_CR22","doi-asserted-by":"publisher","first-page":"1507","DOI":"10.1007\/s00424-017-2042-7","volume":"469","author":"E Giehl","year":"2017","unstructured":"Giehl E, Lemos FO, Huang Y, Giordano FJ, Kuo IY, Ehrlich BE (2017) Polycystin 2-dependent cardio-protective mechanisms revealed by cardiac stress. Eur J Phys 469:1507\u20131517","journal-title":"Eur J Phys"},{"key":"4004_CR23","doi-asserted-by":"publisher","first-page":"44","DOI":"10.2174\/1573402111309010008","volume":"9","author":"MV Irazabal","year":"2013","unstructured":"Irazabal MV, Torres VE (2013) Experimental therapies and ongoing clinical trials to slow down progression of ADPKD. Curr Hypertens Rev 9:44\u201359","journal-title":"Curr Hypertens Rev"},{"key":"4004_CR24","doi-asserted-by":"publisher","first-page":"607","DOI":"10.1172\/JCI76972","volume":"125","author":"VG Gainullin","year":"2015","unstructured":"Gainullin VG, Hopp K, Ward CJ, Hommerding CJ, Harris PC (2015) Polycystin-1 maturation requires polycystin-2 in a dose-dependent manner. J Clin Invest 125:607\u2013620","journal-title":"J Clin Invest"},{"key":"4004_CR25","doi-asserted-by":"publisher","first-page":"82","DOI":"10.2174\/157340310791162659","volume":"6","author":"L Sibal","year":"2010","unstructured":"Sibal L, Agarwal SC, Home PD, Boger RH (2010) The role of asymmetric dimethylarginine (ADMA) in endothelial dysfunction and cardiovascular disease. Curr Cardiol Rev 6:82\u201390","journal-title":"Curr Cardiol Rev"},{"key":"4004_CR26","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.diabres.2008.12.013","volume":"84","author":"F Grover-P\u00e1ez","year":"2009","unstructured":"Grover-P\u00e1ez F, Zavalza-G\u00f3mez AB (2009) Endothelial dysfunction and cardiovascular risk factors. Diabetes Res Clin Pract 84:1\u201310","journal-title":"Diabetes Res Clin Pract"},{"key":"4004_CR27","doi-asserted-by":"publisher","first-page":"502","DOI":"10.1159\/000025693","volume":"36","author":"D Wang","year":"1999","unstructured":"Wang D, Iversen J, Strandgaard S (1999) Contractility and endothelium-dependent relaxation of resistance vessels in polycystic kidney disease rats. J Vasc Res 36:502\u2013509","journal-title":"J Vasc Res"},{"key":"4004_CR28","doi-asserted-by":"publisher","first-page":"854","DOI":"10.1053\/j.ajkd.2004.01.011","volume":"43","author":"O Kocaman","year":"2004","unstructured":"Kocaman O, Oflaz H, Yekeler E, Dursun M, Erdogan D, Demirel S, Alisir S, Turgut F, Mercanoglu F, Ecder T (2004) Endothelial dysfunction and increased carotid intima-media thickness in patients with autosomal dominant polycystic kidney disease. Am J Kidney Dis 43:854\u2013860","journal-title":"Am J Kidney Dis"},{"key":"4004_CR29","doi-asserted-by":"publisher","first-page":"2244","DOI":"10.1111\/j.1523-1755.2005.00682.x","volume":"68","author":"H Oflaz","year":"2005","unstructured":"Oflaz H, Alisir S, Buyukaydin B, Kocaman O, Turgut F, Namli S, Pamukcu B, Oncul A, Ecder T (2005) Biventricular diastolic dysfunction in patients with autosomal-dominant polycystic kidney disease. Kidney Int 68:2244\u20132249","journal-title":"Kidney Int"},{"key":"4004_CR30","doi-asserted-by":"publisher","first-page":"979","DOI":"10.1080\/08860220701641728","volume":"29","author":"F Turgut","year":"2007","unstructured":"Turgut F, Oflaz H, Namli S, Alisir S, Tufan F, Temiz S, Umman S, Ecder T (2007) Ambulatory blood pressure and endothelial dysfunction in patients with autosomal dominant polycystic kidney disease. Ren Fail 29:979\u2013984","journal-title":"Ren Fail"},{"key":"4004_CR31","doi-asserted-by":"publisher","first-page":"986","DOI":"10.2215\/CJN.02330607","volume":"3","author":"K Turkmen","year":"2008","unstructured":"Turkmen K, Oflaz H, Uslu B, Cimen AO, Elitok A (2008) Coronary flow velocity reserve and carotid intima media thickness in patients with autosomal dominant polycystic kidney disease: from impaired tubules to impaired carotid and coronary arteries. Clin J Am Soc Nephrol 3:986\u2013991","journal-title":"Clin J Am Soc Nephrol"},{"key":"4004_CR32","doi-asserted-by":"publisher","first-page":"240","DOI":"10.1159\/000101369","volume":"27","author":"ML Borresen","year":"2007","unstructured":"Borresen ML, Wang D, Strandgaard S (2007) Pulse wave reflection is amplified in normotensive patients with autosomal-dominant polycystic kidney disease and normal renal function. Am J Nephrol 27:240\u2013246","journal-title":"Am J Nephrol"},{"key":"4004_CR33","unstructured":"Widmer RJ, Lerman A (2014) Endothelial dysfunction and cardiovascular disease. Glob Cardiol Sci Pract 2014:291\u2013308"},{"key":"4004_CR34","doi-asserted-by":"publisher","first-page":"2399","DOI":"10.1681\/ASN.2013111184","volume":"25","author":"RW Schrier","year":"2014","unstructured":"Schrier RW, Brosnahan G, Cadnapaphornchai MA, Chonchol M, Friend K, Gitomer B, Rossetti S (2014) Predictors of autosomal dominant polycystic kidney disease progression. J Am Soc Nephrol 25:2399\u20132418","journal-title":"J Am Soc Nephrol"},{"key":"4004_CR35","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1053\/j.ackd.2010.01.001","volume":"17","author":"AB Chapman","year":"2010","unstructured":"Chapman AB, Stepniakowski K, Rahbari-Oskoui F (2010) Hypertension in autosomal dominant polycystic kidney disease. Adv Chronic Kidney Dis 17:153\u2013163","journal-title":"Adv Chronic Kidney Dis"},{"key":"4004_CR36","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1097\/00126097-200306000-00003","volume":"8","author":"T Seeman","year":"2003","unstructured":"Seeman T, Dusek J, Vondrichov\u00e1 H, Kyncl M, John U, Misselwitz J, Janda J (2003) Ambulatory blood pressure correlates with renal volume and number of renal cysts in children with autosomal dominant polycystic kidney disease. Blood Press Monit 8:107\u2013110","journal-title":"Blood Press Monit"},{"key":"4004_CR37","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1007\/s00467-016-3364-y","volume":"32","author":"BV Reddy","year":"2017","unstructured":"Reddy BV, Chapman AB (2017) The spectrum of autosomal dominant polycystic kidney disease in children and adolescents. Pediatr Nephrol 32:31\u201342","journal-title":"Pediatr Nephrol"},{"key":"4004_CR38","doi-asserted-by":"publisher","first-page":"2275","DOI":"10.1007\/s00467-010-1617-8","volume":"25","author":"D Mekahli","year":"2010","unstructured":"Mekahli D, Woolf AS, Bockenhauer D (2010) Similar renal outcomes in children with ADPKD diagnosed by screening or presenting with symptoms. Pediatr Nephrol 25:2275\u20132282","journal-title":"Pediatr Nephrol"},{"key":"4004_CR39","doi-asserted-by":"publisher","first-page":"811","DOI":"10.1053\/j.ajkd.2011.02.379","volume":"57","author":"RW Schrier","year":"2011","unstructured":"Schrier RW (2011) Hypertension and autosomal dominant polycystic kidney disease. Am J Kidney Dis 57:811\u2013813","journal-title":"Am J Kidney Dis"},{"key":"4004_CR40","doi-asserted-by":"publisher","first-page":"F874","DOI":"10.1152\/ajprenal.00209.2017","volume":"313","author":"M Salih","year":"2017","unstructured":"Salih M, Bovee DM, Roksnoer LCW, Casteleijn NF, Bakker SJL, Gansevoort RT, Zietse R, Danser AHJ, Hoorn EJ (2017) Urinary renin-angiotensin markers in polycystic kidney disease. Am J Physiol Renal Physiol 313:F874\u2013F881","journal-title":"Am J Physiol Renal Physiol"},{"key":"4004_CR41","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1038\/ki.2009.128","volume":"76","author":"VE Torres","year":"2009","unstructured":"Torres VE, Harris PC (2009) Autosomal dominant polycystic kidney disease: the last 3 years. Kidney Int 76:149\u2013168","journal-title":"Kidney Int"},{"key":"4004_CR42","doi-asserted-by":"publisher","first-page":"457","DOI":"10.1093\/ckj\/sft031","volume":"6","author":"L Sans-Atxer","year":"2013","unstructured":"Sans-Atxer L, Torra R, Fern\u00e1ndez-Llama P (2013) Hypertension in autosomal-dominant polycystic kidney disease (ADPKD). Clin Kidney J 6:457\u2013463","journal-title":"Clin Kidney J"},{"key":"4004_CR43","doi-asserted-by":"publisher","first-page":"1177","DOI":"10.1038\/ki.1990.330","volume":"38","author":"P Gabow","year":"1990","unstructured":"Gabow P, Chapman A, Johnson A, Tangel D, Duley I, Kaehny W, Manco-Johnson M, Schrier R (1990) Renal structure and hypertension in autosomal dominant polycystic kidney disease. Kidney Int 38:1177\u20131180","journal-title":"Kidney Int"},{"key":"4004_CR44","doi-asserted-by":"crossref","first-page":"1654","DOI":"10.1681\/ASN.V491654","volume":"4","author":"GM Fick","year":"1994","unstructured":"Fick GM, Duley IT, Johnson AM, Strain JD, Manco-Johnson ML, Gabow PA (1994) The spectrum of autosomal dominant polycystic kidney disease in children. J Am Soc Nephrol 4:1654\u20131660","journal-title":"J Am Soc Nephrol"},{"key":"4004_CR45","doi-asserted-by":"publisher","unstructured":"Daenen K, Andries A, Mekahli D, Van Schepdael A, Jouret F, Bammens B (2018) Oxidative stress in chronic kidney disease. Pediatr Nephrol. https:\/\/doi.org\/10.1007\/s00467-018-4005-4","DOI":"10.1007\/s00467-018-4005-4"},{"key":"4004_CR46","doi-asserted-by":"publisher","first-page":"2","DOI":"10.3109\/07853890.2011.653393","volume":"44","author":"AC Montezano","year":"2012","unstructured":"Montezano AC, Touyz RM (2012) Oxidative stress, Noxs, and hypertension: experimental evidence and clinical controversies. Ann Med 44:2\u201316","journal-title":"Ann Med"},{"key":"4004_CR47","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1038\/hr.2010.201","volume":"34","author":"RM Touyz","year":"2011","unstructured":"Touyz RM, Briones AM (2011) Reactive oxygen species and vascular biology: implications in human hypertension. Hypertens Res 34:5\u201314","journal-title":"Hypertens Res"},{"key":"4004_CR48","doi-asserted-by":"publisher","first-page":"369","DOI":"10.2215\/CJN.03780410","volume":"6","author":"MA Cadnapaphornchai","year":"2011","unstructured":"Cadnapaphornchai MA, Masoumi A, Strain JD, McFann K, Schrier RW (2011) Magnetic resonance imaging of kidney and cyst volume in children with ADPKD. Clin J Am Soc Nephrol 6:369\u2013376","journal-title":"Clin J Am Soc Nephrol"},{"key":"4004_CR49","doi-asserted-by":"publisher","first-page":"1192","DOI":"10.1038\/ki.2008.397","volume":"74","author":"MA Cadnapaphornchai","year":"2008","unstructured":"Cadnapaphornchai MA, McFann K, Strain JD, Masoumi A, Schrier RW (2008) Increased left ventricular mass in children with autosomal dominant polycystic kidney disease and borderline hypertension. Kidney Int 74:1192\u20131196","journal-title":"Kidney Int"},{"key":"4004_CR50","doi-asserted-by":"crossref","unstructured":"Zeier M, Geberth S, Schmidt KG, Mandelbaum A, Ritz E (1993) Elevated blood pressure profile and left ventricular mass in children and young adults with autosomal dominant polycystic kidney disease. J Am Soc Nephrol 3:1451\u20131457","DOI":"10.1681\/ASN.V381451"},{"key":"4004_CR51","doi-asserted-by":"crossref","unstructured":"Kocyigit I, Kaya MG, Orscelik O, Kaya C, Akpek M, Zengin H, Sipahioglu MH, Unal A, Yilmaz MI, Tokgoz B, Oymak O, Axelsson J (2012) Early arterial stiffness and inflammatory bio-markers in normotensive polycystic kidney disease patients. Am J Nephrol 26:11\u201318","DOI":"10.1159\/000339440"},{"key":"4004_CR52","doi-asserted-by":"crossref","unstructured":"Chapman AB, Johnson AM, Rainguet S, Hossack K, Gabow P, Schrier RW (1997) Left ventricular hypertrophy in autosomal dominant polycystic kidney disease. J Am Soc Nephrol 8:1292\u20131297","DOI":"10.1681\/ASN.V881292"},{"key":"4004_CR53","doi-asserted-by":"crossref","unstructured":"Pietrzak-Nowacka M, Safranow K, Czechowska M, Dutkiewicz G, Kornacewicz-Jach Z, Ciechanowski K (2012) Autosomal dominant polycystic kidney disease and hypertension are associated with left ventricular mass in a gender-dependent manner. Kidney Blood Press Res 36:301\u2013309","DOI":"10.1159\/000343419"},{"key":"4004_CR54","doi-asserted-by":"publisher","first-page":"597","DOI":"10.2310\/JIM.0b013e31828218e7","volume":"61","author":"O Orscelik","year":"2013","unstructured":"Orscelik O, Kocyigit I, Akpek \u00deM, Dogdu O, Zengin H, Oymak O, Kaya MG (2013) Mean platelet volume and its relation with arterial stiffness in patients with normotensive polycystic kidney disease. J Investig Med 61:597\u2013603","journal-title":"J Investig Med"},{"key":"4004_CR55","doi-asserted-by":"crossref","unstructured":"Martinez-Vea A, Valero FA, Bardaj\u00ed Ruiz A, Gutierrez C, Broch M, Garcia C, Richart C, Oliver JA (2000) Left ventricular hypertrophy in hypertensive patients with autosomal dominant polycystic kidney disease: influence of blood pressure and humoral and neurohormonal factors. Am J Nephrol 20:193\u2013200","DOI":"10.1159\/000013583"},{"key":"4004_CR56","doi-asserted-by":"publisher","first-page":"216","DOI":"10.1053\/j.ajkd.2004.04.026","volume":"44","author":"A Martinez-Vea","year":"2004","unstructured":"Martinez-Vea A, Bardaj\u00ed A, Gutierrez C, Garc\u00eda C, Peralta C, Marcas L, Oliver JA (2004) Exercise blood pressure, cardiac structure, and diastolic function in young normotensive patients with polycystic kidney disease: a prehypertensive state. Am J Kidney Dis 44:216\u2013223","journal-title":"Am J Kidney Dis"},{"key":"4004_CR57","doi-asserted-by":"publisher","first-page":"1029","DOI":"10.1016\/j.amjhyper.2004.06.020","volume":"17","author":"CL Kelleher","year":"2004","unstructured":"Kelleher CL, McFann KK, Johnson AM, Schrier RW (2004) Characteristics of hypertension in young adults with autosomal dominant polycystic kidney disease compared with the general U.S. population. Am J Hypertens 17:1029\u20131034","journal-title":"Am J Hypertens"},{"key":"4004_CR58","doi-asserted-by":"publisher","first-page":"1792","DOI":"10.1046\/j.1523-1755.2003.00264.x","volume":"64","author":"RW Schrier","year":"2003","unstructured":"Schrier RW, Johnson AM, McFann K, Chapman AB (2003) The role of parental hypertension in the frequency and age of diagnosis of hypertension in offspring with autosomal-dominant polycystic kidney disease. Kidney Int 64:1792\u20131799","journal-title":"Kidney Int"},{"key":"4004_CR59","doi-asserted-by":"publisher","first-page":"1366","DOI":"10.1161\/HYPERTENSIONAHA.109.147231","volume":"55","author":"LP Zwan Van Der","year":"2010","unstructured":"Van Der Zwan LP, Scheffer PG, Dekker JM, Stehouwer CDA, Heine RJ, Teerlink T (2010) Hyperglycemia and oxidative stress strengthen the association between myeloperoxidase and blood pressure. Hypertension 55:1366\u20131372","journal-title":"Hypertension"},{"key":"4004_CR60","doi-asserted-by":"publisher","first-page":"185","DOI":"10.2337\/dc08-s246","volume":"31","author":"E Grossman","year":"2008","unstructured":"Grossman E (2008) Does increased oxidative stress cause hypertension? Diabetes Care 31:185\u2013189","journal-title":"Diabetes Care"},{"key":"4004_CR61","doi-asserted-by":"publisher","first-page":"2255","DOI":"10.1056\/NEJMoa1402685","volume":"371","author":"RW Schrier","year":"2014","unstructured":"Schrier RW, Abebe KZ, Perrone RD, Torres VE, Braun WE, Steinman TI, Winklhofer FT, Brosnahan G, Czarnecki PG, Hogan MC, Miskulin DC, Rahbari-Oskoui FF, Grantham JJ, Harris PC, Flessner MF, Bae KT, Moore CG, Chapman AB (2014) Blood pressure in early autosomal dominant polycystic kidney disease. N Engl J Med 371:2255\u20132266","journal-title":"N Engl J Med"},{"key":"4004_CR62","doi-asserted-by":"publisher","first-page":"592","DOI":"10.1007\/s004670050343","volume":"11","author":"T Seeman","year":"1997","unstructured":"Seeman T, Sikut M, Konrad M, Vondrichov\u00e1 H, Janda J, Sch\u00e4rer K (1997) Blood pressure and renal function in autosomal dominant polycystic kidney disease. Pediatr Nephrol 11:592\u2013596","journal-title":"Pediatr Nephrol"},{"key":"4004_CR63","first-page":"629","volume":"53","author":"T Seeman","year":"2004","unstructured":"Seeman T, Dusek J, Vondr\u00e1k K, Bl\u00e1hov\u00e1 K, Simkov\u00e1 E, Kreisinger J, Dvor\u00e1k P, Kyncl M, Hr\u00edbal Z, Janda J (2004) Renal concentrating capacity is linked to blood pressure in children with autosomal dominant polycystic kidney disease. Physiol Res 53:629\u2013634","journal-title":"Physiol Res"},{"key":"4004_CR64","doi-asserted-by":"publisher","first-page":"856","DOI":"10.1053\/j.ajkd.2011.01.023","volume":"57","author":"C Patch","year":"2011","unstructured":"Patch C, Charlton J, Roderick PJ, Gulliford MC (2011) Use of antihypertensive medications and mortality of patients with autosomal dominant polycystic kidney disease: a population-based study. Am J Kidney Dis 57:856\u2013862","journal-title":"Am J Kidney Dis"},{"key":"4004_CR65","doi-asserted-by":"publisher","first-page":"820","DOI":"10.2215\/CJN.02810608","volume":"4","author":"MA Cadnapaphornchai","year":"2009","unstructured":"Cadnapaphornchai MA, Mcfann K, Strain JD, Masoumi A, Schrier RW (2009) Prospective change in renal volume and function in children with ADPKD. Clin J Am Soc Nephrol 4:820\u2013829","journal-title":"Clin J Am Soc Nephrol"},{"key":"4004_CR66","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1038\/ki.2015.59","volume":"88","author":"AB Chapman","year":"2015","unstructured":"Chapman AB, Devuyst O, Eckardt K-U, Gansevoort RT, Harris T, Horie S, Kasiske BL, Odland D, Pei Y, Perrone RD, Pirson Y, Schrier RW, Torra R, Torres VE, Watnick T, Wheeler DC (2015) Autosomal-dominant polycystic kidney disease (ADPKD): executive summary from a kidney disease: improving global outcomes (KDIGO) controversies conference. Kidney Int 88:17\u201327","journal-title":"Kidney Int"},{"key":"4004_CR67","first-page":"e13","volume":"71","author":"PK Whelton","year":"2017","unstructured":"Whelton PK, Carey RM, Aronow WS, Ovbiagele B, Casey DE, Smith SC, Collins KJ, Spencer CC, Himmelfarb CD, Stafford RS, Depalma SM, Taler SJ, Gidding S, Thomas RJ, Jamerson KA, Williams KA, Jones DW, Williamson JD, Maclaughlin EJ, Wright JT, Mauri L (2017) 2017 ACC\/AHA\/AAPA\/ABC\/ACPM\/AGS\/APhA\/ASH\/ASPC\/NMA\/PCNA guideline for the prevention, detection, evaluation, and management of high blood pressure in adults: a report of the American College of Cardiology \/ American Heart Association Task Force on Clinical Practice Guidelines. J Am Coll Cardiol 71:e13\u2013e115","journal-title":"J Am Coll Cardiol"},{"key":"4004_CR68","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1186\/s40064-016-1871-8","volume":"5","author":"S Sag","year":"2016","unstructured":"Sag S, Yildiz A, Gullulu S, Gungoren F, Ozdemir B, Cegilli E (2016) Early atherosclerosis in normotensive patients with autosomal dominant polycystic kidney disease: the relation between epicardial adipose tissue thickness and carotid intima - media thickness. Springerplus 5:211\u2013217","journal-title":"Springerplus"},{"key":"4004_CR69","doi-asserted-by":"publisher","first-page":"243","DOI":"10.1007\/s12265-012-9359-6","volume":"5","author":"JA Chirinos","year":"2012","unstructured":"Chirinos JA (2012) Arterial stiffness: basic concepts and measurement techniques. J Cardiovasc Transl Res 5:243\u2013255","journal-title":"J Cardiovasc Transl Res"},{"key":"4004_CR70","doi-asserted-by":"publisher","first-page":"2508","DOI":"10.2215\/CJN.04610511","volume":"6","author":"RD Perrone","year":"2011","unstructured":"Perrone RD, Abebe KZ, Schrier RW, Chapman AB, Torres VE, Bost J, Kaya D, Miskulin DC, Steinman TI, Braun W, Winklhofer FT, Hogan MC, Rahbari-Oskoui F, Kelleher C, Masoumi A, Glockner J, Halin NJ, Martin D, Remer E, Patel N, Pedrosa I, Wetzel LH, Thompson PA, Miller JP, Meyers CM, Bae KT (2011) Cardiac magnetic resonance assessment of left ventricular mass in autosomal dominant polycystic kidney disease. Clin J Am Soc Nephrol 6:2508\u20132515","journal-title":"Clin J Am Soc Nephrol"},{"key":"4004_CR71","doi-asserted-by":"publisher","first-page":"222","DOI":"10.5830\/CVJA-2011-068","volume":"23","author":"M Mudau","year":"2012","unstructured":"Mudau M, Genis A, Lochner A, Strijdom H (2012) Endothelial dysfunction: the early predictor of atherosclerosis. Cardiovasc J Afr 23:222\u2013231","journal-title":"Cardiovasc J Afr"},{"key":"4004_CR72","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1111\/j.1476-5381.2010.01196.x","volume":"164","author":"U F\u00f6rstermann","year":"2011","unstructured":"F\u00f6rstermann U, Li H (2011) Therapeutic effect of enhancing endothelial nitric oxide synthase (eNOS) expression and preventing eNOS uncoupling. Br J Pharmacol 164:213\u2013223","journal-title":"Br J Pharmacol"},{"key":"4004_CR73","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1016\/j.coph.2013.01.006","volume":"13","author":"H Li","year":"2013","unstructured":"Li H, F\u00f6rstermann U (2013) Uncoupling of endothelial NO synthase in atherosclerosis and vascular disease. Curr Opin Pharmacol 13:161\u2013167","journal-title":"Curr Opin Pharmacol"},{"key":"4004_CR74","doi-asserted-by":"publisher","first-page":"752","DOI":"10.1053\/j.ajkd.2006.08.015","volume":"48","author":"E Dounousi","year":"2006","unstructured":"Dounousi E, Papavasiliou E, Makedou A, Ioannou K, Katopodis KP, Tselepis A, Siamopoulos KC, Tsakiris D (2006) Oxidative stress is progressively enhanced with advancing stages of CKD. Am J Kidney Dis 48:752\u2013760","journal-title":"Am J Kidney Dis"},{"key":"4004_CR75","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1053\/j.ajkd.2005.09.029","volume":"47","author":"MI Yilmaz","year":"2006","unstructured":"Yilmaz MI, Saglam M, Caglar K, Cakir E, Sonmez A, Ozgurtas T, Aydin A, Eyileten T, Ozcan O, Acikel C, Tasar M, Genctoy G, Erbil K, Vural A, Zoccali C (2006) The determinants of endothelial dysfunction in CKD: oxidative stress and asymmetric dimethylarginine. Am J Kidney Dis 47:42\u201350","journal-title":"Am J Kidney Dis"},{"key":"4004_CR76","doi-asserted-by":"publisher","first-page":"411","DOI":"10.1253\/circj.CJ-08-1102","volume":"73","author":"Y Higashi","year":"2009","unstructured":"Higashi Y, Noma K, Yoshizumi M, Kihara Y (2009) Endothelial function and oxidative stress in cardiovascular diseases. Circ J 73:411\u2013418","journal-title":"Circ J"},{"key":"4004_CR77","doi-asserted-by":"publisher","first-page":"7","DOI":"10.2215\/CJN.04140510","volume":"6","author":"V Menon","year":"2011","unstructured":"Menon V, Rudym D, Chandra P, Miskulin D, Perrone R, Sarnak M (2011) Inflammation, oxidative stress, and insulin resistance in polycystic kidney disease. Clin J Am Soc Nephrol 6:7\u201313","journal-title":"Clin J Am Soc Nephrol"},{"key":"4004_CR78","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1159\/000355756","volume":"38","author":"V Raptis","year":"2013","unstructured":"Raptis V, Georgianos PI, Sarafidis PA, Sioulis A, Makedou K, Makedou A, Grekas DM, Kapoulas S (2013) Elevated asymmetric dimethylarginine is associated with oxidant stress aggravation in patients with early stage autosomal dominant polycystic kidney disease. Kidney Blood Press Res 38:72\u201382","journal-title":"Kidney Blood Press Res"},{"key":"4004_CR79","doi-asserted-by":"publisher","first-page":"358","DOI":"10.1111\/j.1600-0463.2004.apm1120606.x","volume":"112","author":"D Wang","year":"2004","unstructured":"Wang D, Braendstrup O, Larsen S, Horn T, Strandgaard S (2004) The expression and activity of renal nitric oxide synthase and circulating nitric oxide in polycystic kidney disease rats. APMIS 112:358\u2013368","journal-title":"APMIS"},{"key":"4004_CR80","doi-asserted-by":"publisher","first-page":"F53","DOI":"10.1152\/ajprenal.00041.2008","volume":"295","author":"M Zhou","year":"2008","unstructured":"Zhou M, Schuman I, Jaimes E, Raij L (2008) Renoprotection by statins is linked to a decrease in renal oxidative stress, TGF-beta, and fibronectin with concomitant increase in nitric oxide bioavailability. Am J Physiol Renal Physiol 295:F53\u2013F59","journal-title":"Am J Physiol Renal Physiol"},{"key":"4004_CR81","doi-asserted-by":"publisher","first-page":"1004","DOI":"10.1038\/79510","volume":"6","author":"Y Kureishi","year":"2000","unstructured":"Kureishi Y, Luo Z, Shiojima I, Bialik A, Fulton D, Lefer DJ, Sessa WC, Walsh K (2000) The HMG-CoA reductase inhibitor simvastatin activates the protein kinase Akt and promotes angiogenesis in normocholesterolemic animals. Nat Med 6:1004\u20131010","journal-title":"Nat Med"},{"key":"4004_CR82","doi-asserted-by":"publisher","first-page":"719","DOI":"10.1007\/s00228-002-0556-0","volume":"58","author":"U Laufs","year":"2003","unstructured":"Laufs U (2003) Beyond lipid-lowering: effects of statins on endothelial nitric oxide. Eur J Clin Pharmacol 58:719\u2013731","journal-title":"Eur J Clin Pharmacol"},{"key":"4004_CR83","doi-asserted-by":"crossref","unstructured":"Helal I, McFann K, Reed B, Yan XD, Schrier RW, Fick-Brosnahan GM (2013) Serum uric acid, kidney volume and progression in autosomal-dominant polycystic kidney disease. Nephrol Dial Transplant 28:380\u2013385","DOI":"10.1093\/ndt\/gfs417"},{"key":"4004_CR84","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1159\/000353730","volume":"123","author":"I Kocyigit","year":"2013","unstructured":"Kocyigit I, Yilmaz MI, Orscelik O, Sipahioglu MH, Unal A, Eroglu E, Kalay N, Tokgoz B, Axelsson J, Oymak O (2013) Serum uric acid levels and endothelial dysfunction in patients with autosomal dominant polycystic kidney disease. Nephron Clin Pract 123:157\u2013164","journal-title":"Nephron Clin Pract"},{"key":"4004_CR85","doi-asserted-by":"crossref","unstructured":"Ishimoto Y, Inagi R, Yoshihara D, Kugita M, Nagao S, Shimizu A, Takeda N, Wake M, Honda K, Zhou J, Nangaku M (2017) Mitochondrial abnormality facilitates cyst formation in autosomal dominant polycystic kidney disease. Mol Cell Biol 37:e00337-17","DOI":"10.1128\/MCB.00337-17"},{"key":"4004_CR86","doi-asserted-by":"publisher","first-page":"528","DOI":"10.1038\/nature17184","volume":"531","author":"MT Tran","year":"2016","unstructured":"Tran MT, Zsengeller ZK, Berg AH, Khankin EV, Bhasin MK, Kim W, Clish CB, Stillman IE, Karumanchi SA, Rhee EP, Parikh SM (2016) PGC1\u03b1 drives NAD biosynthesis linking oxidative metabolism to renal protection. Nature 531:528\u2013532","journal-title":"Nature"},{"key":"4004_CR87","doi-asserted-by":"publisher","first-page":"1109","DOI":"10.1016\/j.cell.2006.11.013","volume":"127","author":"M Lagouge","year":"2006","unstructured":"Lagouge M, Argmann C, Gerhart-Hines Z, Meziane H, Lerin C, Daussin F, Messadeq N, Milne J, Lambert P, Elliott P, Geny B, Laakso M, Puigserver P, Auwerx J (2006) Resveratrol improves mitochondrial function and protects against metabolic disease by activating SIRT1 and PGC-1\u03b1. Cell 127:1109\u20131122","journal-title":"Cell"},{"key":"4004_CR88","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1007\/s11010-015-2576-y","volume":"411","author":"Y Zhou","year":"2016","unstructured":"Zhou Y, Lin S, Zhang L, Li Y (2016) Resveratrol prevents renal lipotoxicity in high-fat diet-treated mouse model through regulating PPAR-\u03b1 pathway. Mol Cell Biochem 411:143\u2013150","journal-title":"Mol Cell Biochem"},{"key":"4004_CR89","doi-asserted-by":"publisher","first-page":"675","DOI":"10.1016\/j.cmet.2012.04.003","volume":"15","author":"NL Price","year":"2012","unstructured":"Price NL, Gomes AP, Ling AJY, Duarte FV, Martin-Montalvo A, North BJ, Agarwal B, Ye L, Ramadori G, Teodoro JS, Hubbard BP, Varela AT, Davis JG, Varamini B, Hafner A, Moaddel R, Rolo AP, Coppari R, Palmeira CM, de Cabo R, Baur JA, Sinclair DA (2012) SIRT1 is required for AMPK activation and the beneficial effects of resveratrol on mitochondrial function. Cell Metab 15:675\u2013690","journal-title":"Cell Metab"},{"key":"4004_CR90","doi-asserted-by":"publisher","first-page":"1826","DOI":"10.1093\/ndt\/gfw058","volume":"31","author":"M Wu","year":"2016","unstructured":"Wu M, Gu J, Mei S, Xu D, Jing Y, Yao Q, Chen M, Yang M, Chen S, Yang B, Qi N, Hu H, W\u00fcthrich RP, Mei C (2016) Resveratrol delays polycystic kidney disease progression through attenuation of nuclear factor \u03bab-induced inflammation. Nephrol Dial Transplant 31:1826\u20131834","journal-title":"Nephrol Dial Transplant"},{"key":"4004_CR91","doi-asserted-by":"publisher","first-page":"2144","DOI":"10.1093\/ndt\/gfx289","volume":"32","author":"M Chang","year":"2017","unstructured":"Chang M, Ong ACM (2017) Targeting new cellular disease pathways in autosomal dominant polycystic kidney disease. Nephrol Dial Transplant 32:2144","journal-title":"Nephrol Dial Transplant"},{"key":"4004_CR92","doi-asserted-by":"publisher","first-page":"437","DOI":"10.1016\/j.cct.2011.01.008","volume":"32","author":"MA Cadnapaphornchai","year":"2011","unstructured":"Cadnapaphornchai MA, George DM, Masoumi A, Mcfann K, Strain JD, Schrier RW (2011) Effect of statin therapy on disease progression of pediatric ADPKD: design and baseline characteristics of participants. Contemp Clin Trials 32:437\u2013445","journal-title":"Contemp Clin Trials"},{"key":"4004_CR93","doi-asserted-by":"publisher","first-page":"889","DOI":"10.2215\/CJN.08350813","volume":"9","author":"MA Cadnapaphornchai","year":"2014","unstructured":"Cadnapaphornchai MA, George DM, McFann K, Wang W, Gitomer B, Strain JD, Schrier RW (2014) Effect of pravastatin on total kidney volume, left ventricular mass index, and microalbuminuria in pediatric autosomal dominant polycystic kidney disease. Clin J Am Soc Nephrol 9:889\u2013896","journal-title":"Clin J Am Soc Nephrol"},{"key":"4004_CR94","doi-asserted-by":"publisher","first-page":"1534","DOI":"10.2215\/CJN.11331114","volume":"10","author":"J Klawitter","year":"2015","unstructured":"Klawitter J, McFann K, Pennington AT, Wang W, Klawitter J, Christians U, Schrier RW, Gitomer B, Cadnapaphornchai MA (2015) Pravastatin therapy and biomarker changes in children and young adults with autosomal dominant polycystic kidney disease. Clin J Am Soc Nephrol 10:1534\u20131541","journal-title":"Clin J Am Soc Nephrol"},{"key":"4004_CR95","first-page":"1","volume":"13","author":"G Brosnahan","year":"2017","unstructured":"Brosnahan G, Abebe KZ, Rahbari-Oskoui FF, Patterson CG, Bae KT, Schrier RW, Braun WE, Chapman AB, Flessner MF, Harris PC, Perrone RD, Steinman TI, Torres VE (2017) Effect of statin therapy on the progression of autosomal dominant polycystic kidney disease. A secondary analysis of the HALT PKD trials. Curr Hypertens Rev 13:1\u201311","journal-title":"Curr Hypertens Rev"},{"key":"4004_CR96","doi-asserted-by":"publisher","first-page":"1000","DOI":"10.1158\/0008-5472.CAN-08-2367","volume":"69","author":"CS Beevers","year":"2009","unstructured":"Beevers CS, Chen L, Liu L, Luo Y, Webster NJG, Huang S (2009) Curcumin disrupts the mammalian target of rapamycin-raptor complex. Cancer Res 69:1000\u20131008","journal-title":"Cancer Res"},{"key":"4004_CR97","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1016\/j.canlet.2008.03.009","volume":"269","author":"AB Kunnumakkara","year":"2008","unstructured":"Kunnumakkara AB, Anand P, Aggarwal BB (2008) Curcumin inhibits proliferation, invasion, angiogenesis and metastasis of different cancers through interaction with multiple cell signaling proteins. Cancer Lett 269:199\u2013225","journal-title":"Cancer Lett"},{"key":"4004_CR98","doi-asserted-by":"publisher","first-page":"F1193","DOI":"10.1152\/ajprenal.00419.2010","volume":"300","author":"WN Leonhard","year":"2011","unstructured":"Leonhard WN, van der Wal A, Novalic Z, Kunnen SJ, Gansevoort RT, Breuning MH, de Heer E, Peters DJM (2011) Curcumin inhibits cystogenesis by simultaneous interference of multiple signaling pathways: in vivo evidence from a Pkd1-deletion model. Am J Physiol Renal Physiol 300:F1193\u2013F1202","journal-title":"Am J Physiol Renal Physiol"},{"key":"4004_CR99","doi-asserted-by":"publisher","first-page":"92","DOI":"10.1016\/j.ejphar.2010.12.008","volume":"654","author":"J Gao","year":"2011","unstructured":"Gao J, Zhou H, Lei T, Zhou L, Li W, Li X, Yang B (2011) Curcumin inhibits renal cyst formation and enlargement in vitro by regulating intracellular signaling pathways. Eur J Pharmacol 654:92\u201399","journal-title":"Eur J Pharmacol"},{"key":"4004_CR100","doi-asserted-by":"publisher","first-page":"664","DOI":"10.3349\/ymj.2016.57.3.664","volume":"57","author":"BH Kim","year":"2016","unstructured":"Kim BH, Lee ES, Choi R, Nawaboot J, Lee MY, Lee EY, Kim HS, Chung CH (2016) Protective effects of curcumin on renal oxidative stress and lipid metabolism in a rat model of type 2 diabetic nephropathy. Yonsei Med J 57:664\u2013673","journal-title":"Yonsei Med J"},{"key":"4004_CR101","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1111\/bcpt.12817","volume":"122","author":"BH Ali","year":"2018","unstructured":"Ali BH, Al-Salam S, Suleimani Y, Kalbani J, Bahlani S, Ashique M, Manoj P, Dhahli B, Abri N, Naser HT, Yasin J, Nemmar A, Za\u2019abi M, Hartmann C, Schupp N (2018) Curcumin ameliorates kidney function and oxidative stress in experimental chronic kidney disease. Basic Clin Pharmacol Toxicol 122:65\u201373","journal-title":"Basic Clin Pharmacol Toxicol"},{"key":"4004_CR102","doi-asserted-by":"publisher","first-page":"233","DOI":"10.1016\/j.cbi.2011.03.014","volume":"192","author":"AA Alhaider","year":"2011","unstructured":"Alhaider AA, Korashy HM, Sayed-Ahmed MM, Mobark M, Kfoury H, Mansour MA (2011) Metformin attenuates streptozotocin-induced diabetic nephropathy in rats through modulation of oxidative stress genes expression. Chem Biol Interact 192:233\u2013242","journal-title":"Chem Biol Interact"},{"key":"4004_CR103","doi-asserted-by":"publisher","first-page":"383","DOI":"10.3892\/etm.2017.4475","volume":"14","author":"S Zhang","year":"2017","unstructured":"Zhang S, Xu H, Yu X, Wu Y, Sui D (2017) Metformin ameliorates diabetic nephropathy in a rat model of low-dose streptozotocin-induced diabetes. Exp Ther Med 14:383\u2013390","journal-title":"Exp Ther Med"},{"key":"4004_CR104","first-page":"1591","volume":"466","author":"D Mekahli","year":"2014","unstructured":"Mekahli D, Decuypere JP, Sammels E, Welkenhuyzen K, Schoeber J, Audrezet MP, Corvelyn A, Dech\u00eanes G, Ong ACM, Wilmer MJ, Van Den Heuvel L, Bultynck G, Parys JB, Missiaen L, Levtchenko E, De Smedt H (2014) Polycystin-1 but not polycystin-2 deficiency causes upregulation of the mTOR pathway and can be synergistically targeted with rapamycin and metformin. Pflugers Arch Eur J Physiol 466:1591\u20131604","journal-title":"Pflugers Arch Eur J Physiol"},{"key":"4004_CR105","doi-asserted-by":"publisher","first-page":"2462","DOI":"10.1073\/pnas.1011498108","volume":"108","author":"V Takiar","year":"2011","unstructured":"Takiar V, Nishio S, Seo-Mayer P, King JD, Li H, Zhang L, Karihaloo A, Hallows KR, Somlo S, Caplan MJ (2011) Activating AMP-activated protein kinase (AMPK) slows renal cystogenesis. Proc Natl Acad Sci U S A 108:2462\u20132467","journal-title":"Proc Natl Acad Sci U S A"},{"key":"4004_CR106","doi-asserted-by":"publisher","first-page":"7161","DOI":"10.1038\/s41598-017-07300-x","volume":"7","author":"MY Chang","year":"2017","unstructured":"Chang MY, Ma TL, Hung CC, Tian YC, Chen YC, Yang CW, Cheng YC (2017) Metformin inhibits cyst formation in a zebrafish model of polycystin-2 deficiency. Sci Rep 7:7161","journal-title":"Sci Rep"},{"key":"4004_CR107","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1007\/s11606-017-4219-3","volume":"33","author":"ZA Marcum","year":"2018","unstructured":"Marcum ZA, Forsberg CW, Moore KP, de Boer IH, Smith NL, Boyko EJ, Floyd JS (2018) Mortality associated with metformin versus sulfonylurea initiation: a cohort study of veterans with diabetes and chronic kidney disease. J Gen Intern Med 33:155\u2013165","journal-title":"J Gen Intern Med"},{"key":"4004_CR108","doi-asserted-by":"publisher","first-page":"465","DOI":"10.1152\/ajprenal.00460.2010","volume":"300","author":"D Yoshihara","year":"2011","unstructured":"Yoshihara D, Kurahashi H, Morita M, Kugita M, Hiki Y, Aukema HM, Yamaguchi T, Calvet JP, Wallace DP, Nagao S (2011) PPAR-\u03b3 agonist ameliorates kidney and liver disease in an orthologous rat model of human autosomal recessive polycystic kidney disease. Am J Physiol Renal Physiol 300:465\u2013474","journal-title":"Am J Physiol Renal Physiol"},{"key":"4004_CR109","doi-asserted-by":"publisher","first-page":"1731","DOI":"10.1093\/hmg\/11.15.1731","volume":"11","author":"S Muto","year":"2002","unstructured":"Muto S, Aiba A, Saito Y, Nakao K, Nakamura K, Tomita K, Kitamura T, Kurabayashi M, Nagai R, Higashihara E, Harris PC, Katsuki M, Horie S (2002) Pioglitazone improves the phenotype and molecular defects of a targeted Pkd1 mutant. Hum Mol Genet 11:1731\u20131742","journal-title":"Hum Mol Genet"},{"key":"4004_CR110","doi-asserted-by":"publisher","first-page":"1831","DOI":"10.1159\/000443121","volume":"38","author":"L Sun","year":"2016","unstructured":"Sun L, Yuan Q, Xu T, Yao L, Feng J, Ma J, Wang L, Lu C, Wang D (2016) Pioglitazone, a peroxisome proliferator-activated receptor gamma agonist, ameliorates chronic kidney disease by enhancing antioxidative capacity and attenuating angiogenesis in the kidney of a 5\/6 nephrectomized rat model. Cell Physiol Biochem 38:1831\u20131840","journal-title":"Cell Physiol Biochem"}],"container-title":["Pediatric Nephrology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00467-018-4004-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00467-018-4004-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00467-018-4004-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,8,28]],"date-time":"2022-08-28T23:51:10Z","timestamp":1661730670000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00467-018-4004-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,8,13]]},"references-count":110,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2019,6]]}},"alternative-id":["4004"],"URL":"https:\/\/doi.org\/10.1007\/s00467-018-4004-5","relation":{},"ISSN":["0931-041X","1432-198X"],"issn-type":[{"value":"0931-041X","type":"print"},{"value":"1432-198X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,8,13]]},"assertion":[{"value":"15 June 2017","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 June 2018","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 June 2018","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 August 2018","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"DM is supported by the Clinical Research Fund of UZ Leuven, by the Fund for Scientific Research G0B1313N, and by a research grant from the European Society for Pediatric Nephrology. FJ is a Fellow of the Fonds National de la Recherche Scientifique.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}